Possibilities of applying antigestagens in therapy
| Autor: | Yanina A Lebedeva, Yuri N. Fedotov, Evgeniа B. Troik, Oleg L. Molchanov |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pregnancy
medicine.medical_specialty 030219 obstetrics & reproductive medicine Uterine leiomyoma Uterine fibroids Obstetrics business.industry Obstetrics and Gynecology Cancer Myoma Mifepristone medicine.disease Meningioma 03 medical and health sciences 0302 clinical medicine Breast cancer medicine 030212 general & internal medicine business medicine.drug |
| Zdroj: | Journal of obstetrics and women's diseases. 68:51-58 |
| ISSN: | 1683-9366 1684-0461 |
| DOI: | 10.17816/jowd68251-58 |
| Popis: | In the modern medical practice, anti-progestogen therapy is widely used where RU-486 (mifepristone) is one of its variants. However, the potential of this therapy in the treatment of various pathologies is far from exhausted. In the general medical practice, it is possible to use mifepristone (RU486 metabolite) to control hyperglycemia in patients with Cushing’s syndrome, in the treatment of endogenous hypercorticism syndrome and metastatic cancer (melanoma, breast cancer, meningioma and other localizations). In the gynecological practice, it is used for contraception and early termination of pregnancy. Of particular interest is the use of antigestagens in the therapy of uterine leiomyoma. In recent years, the conservative treatment of uterine leiomyoma, aimed at the restoration and preservation of women’s reproductive health, has become a priority task for specialists. Therapy with antigestagens, in particular mifepristone, is seen as a possible worthy alternative to invasive methods of treating uterine fibroids, in which there are still many “white spots” that need to be studied. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|